Patritumab deruxtecan

DB21996InvestigationalProtein Based Therapies

Patritumab deruxtecan is under investigation in clinical trial NCT06596694 (Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)).

Mechanism: Pharmacologically active on DNA topoisomerase 1 and Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Also known as: HER3-DXd
Code names: MK-1022 · U3-1402 · U3-1402A

Resolves to

Compound

UNII3XPI7EG4W8CAS2227102-46-5

Clinical / RWD

ATCL01FX36

Targets

P11387TOP1P21860ERBB3

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

28Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 14 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Patritumab deruxtecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account